Patents by Inventor Esteban Dominguez-Manzanares

Esteban Dominguez-Manzanares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8097652
    Abstract: The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: January 17, 2012
    Assignee: Eli Lilly and Company
    Inventor: Esteban Dominguez-Manzanares
  • Patent number: 7838543
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: November 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: James Peter Beck, Brian David Wakefield, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Kevin Matthew Gardinier, Peter Michael Greenen, Kenneth Allen Savin
  • Patent number: 7652064
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: January 26, 2010
    Assignee: Eli Lilly and Company
    Inventor: Esteban Dominguez-Manzanares
  • Publication number: 20100010090
    Abstract: The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Application
    Filed: December 6, 2007
    Publication date: January 14, 2010
    Inventor: Esteban Dominguez-Manzanares
  • Patent number: 7642361
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: January 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano, Maria Carmen Fernandez, William Joseph Hornback, Alma Maria Jimenez-Aguado, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 7625932
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: December 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang, Paul Leslie Ornstein, Michelle Lee Thompson, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Ana Maria Castano Mansanet, Larry Gene Huffman, William David Miller
  • Publication number: 20090170913
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Application
    Filed: December 16, 2005
    Publication date: July 2, 2009
    Inventors: James Peter Beck, Brian David Wakefield, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Kevin Matthew Gardinier, Peter Michael Greenen, Kenneth Allen Savin
  • Patent number: 7393868
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: July 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Ana Maria Castano Mansanet, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang
  • Publication number: 20070142441
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Application
    Filed: June 5, 2006
    Publication date: June 21, 2007
    Inventors: Ana Castano Mansanet, Frederic Cordier, Esteban Dominguez-Manzanares, Jian Hong, William Hornback, Delu Jiang
  • Publication number: 20070105852
    Abstract: The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
    Type: Application
    Filed: January 5, 2005
    Publication date: May 10, 2007
    Inventors: Ana Castano Mansanet, Esteban Dominguez-Manzanares, Ana Escribano, Maria Fernandez, William Hornback, Alma Jimenez-Aguado, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman
  • Publication number: 20070066573
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Application
    Filed: September 27, 2004
    Publication date: March 22, 2007
    Inventors: Pamela Albaugh, Esteban Dominguez-Manzanares, Jian Hong, William Hornback, Delu Jiang, Paul Ornstein, Michelle Thompson, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman, Ana Castano Mansanet, Larry Huffman, William Miller
  • Publication number: 20060276532
    Abstract: The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.
    Type: Application
    Filed: June 6, 2006
    Publication date: December 7, 2006
    Inventor: Esteban Dominguez-Manzanares
  • Publication number: 20060100237
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 14, 2005
    Publication date: May 11, 2006
    Inventors: Macklin Arnold, Thomas Bleisch, Ana Castano Mansanet, Esteban Dominguez-Manzanares, Jose Martinez-Perez, Paul Ornstein, Mark Winter
  • Patent number: 6924294
    Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: August 2, 2005
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano
  • Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Publication number: 20040053961
    Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Application
    Filed: June 12, 2003
    Publication date: March 18, 2004
    Inventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez Manzanares, Ana Maria Escribano